Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 99.31M | 71.43M | 86.77M | 67.46M | 59.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.31M | 71.43M | 86.77M | 67.46M | 59.95M |
| Cost of Revenue | 43.60M | 42.50M | 43.11M | 38.48M | 48.88M |
| Gross Profit | 55.72M | 28.93M | 43.66M | 28.98M | 11.07M |
| SG&A Expenses | 39.27M | 38.95M | 36.40M | 34.56M | 37.57M |
| Depreciation & Amortization | 9.50M | 8.54M | 9.52M | 9.01M | 9.35M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 151.22M | 152.47M | 160.23M | 157.21M | 173.73M |
| Operating Income | -51.91M | -81.04M | -73.46M | -89.76M | -113.77M |
| Income Before Tax | -48.69M | -79.71M | -71.72M | -93.66M | -109.67M |
| Income Tax Expenses | -1.37M | -665.00K | 184.00K | -2.41M | 1.99M |
| Earnings from Continuing Operations | -47.32M | -79.05M | -71.90M | -91.25M | -111.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.32M | -79.05M | -71.90M | -91.25M | -111.66M |
| EBIT | -51.91M | -81.04M | -73.46M | -89.76M | -113.77M |
| EBITDA | -42.41M | -72.50M | -63.53M | -81.00M | -104.42M |
| EPS Basic | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 |
| Normalized Basic EPS | -0.07 | -0.12 | -0.11 | -0.15 | -0.20 |
| EPS Diluted | -0.11 | -0.19 | -0.18 | -0.25 | -0.33 |
| Normalized Diluted EPS | -0.07 | -0.12 | -0.11 | -0.15 | -0.20 |
| Average Basic Shares Outstanding | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M |
| Average Diluted Shares Outstanding | 450.19M | 418.51M | 406.97M | 364.04M | 334.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |